A systematic literature review on the efficacy-effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs

被引:24
作者
Ankarfeldt, Mikkel Z. [1 ,2 ]
Adalsteinsson, Erpur [1 ]
Groenwold, Rolf H. H. [2 ,3 ]
Ali, M. Sanni [2 ,3 ,4 ]
Klungel, Olaf H. [2 ,3 ]
机构
[1] Novo Nordisk AS, Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
[3] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands
[4] Univ Oxford, Nuffield Dept Orthopaed, Rheumatol, Musculoskeletal Sci, Oxford, England
来源
CLINICAL EPIDEMIOLOGY | 2017年 / 9卷
关键词
efficacy-effectiveness gap; diabetes mellitus; type; 2; glucose-lowering drugs; hemoglobin A1c; literature review; TYPE-2; DIABETES-MELLITUS; ACHIEVE GLYCEMIC CONTROL; ONCE-WEEKLY EXENATIDE; VS. INSULIN GLARGINE; LONG-ACTING INSULIN; OPEN-LABEL; DOUBLE-BLIND; ADD-ON; JAPANESE PATIENTS; VILDAGLIPTIN VS;
D O I
10.2147/CLEP.S121991
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Aim: To identify a potential efficacy-effectiveness gap and possible explanations (drivers of effectiveness) for differences between results of randomized controlled trials (RCTs) and observational studies investigating glucose-lowering drugs. Methods: A systematic literature review was conducted in English language articles published between 1 January, 2000 and 31 January, 2015 describing either RCTs or observational studies comparing glucagon-like peptide-1 analogs (GLP-1) with insulin or comparing dipeptidyl peptidase-4 inhibitors (DPP-4i) with sulfonylurea, all with change in glycated hemoglobin (HbA1c) as outcome. Medline, Embase, Current Content, and Biosis were searched. Information on effect estimates, baseline characteristics of the study population, publication year, study duration, and number of patients, and for observational studies, characteristics related to confounding adjustment and selection-and information bias were extracted. Results: From 312 hits, 11 RCTs and 7 observational studies comparing GLP-1 with insulin, and from 474 hits, 16 RCTs and 4 observational studies comparing DPP-4i with sulfonylurea were finally included. No differences were observed in baseline characteristics of the study populations (age, sex, body mass index, time since diagnosis of type 2 diabetes mellitus, and HbA1c) or effect sizes across study designs. Mean effect sizes ranged from -0.43 to 0.91 and from -0.80 to 1.13 in RCTs and observational studies, respectively, comparing GLP-1 with insulin, and from -0.13 to 2.70 and -0.20 to 0.30 in RCTs and observational studies, respectively, comparing DPP-4i and sulfonylurea. Generally, the identified observational studies held potential flaws with regard to confounding adjustment and selection-and information bias. Conclusions: Neither potential drivers of effectiveness nor an efficacy-effectiveness gap were identified. However, the limited number of studies and potential problems with confounding adjustment, selection-and information bias in the observational studies, may have hidden a true efficacy-effectiveness gap.
引用
收藏
页码:41 / 51
页数:11
相关论文
共 66 条
  • [1] HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin
    Ahren, Bo
    Johnson, Susan L.
    Stewart, Murray
    Cirkel, Deborah T.
    Yang, Fred
    Perry, Caroline
    Feinglos, Mark N.
    [J]. DIABETES CARE, 2014, 37 (08) : 2141 - 2148
  • [2] Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies
    Ahren, Bo
    Mathieu, Chantal
    Bader, Giovanni
    Schweizer, Anja
    Foley, James E.
    [J]. DIABETOLOGIA, 2014, 57 (07) : 1304 - 1307
  • [3] Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials
    Anglemyer, Andrew
    Horvath, Hacsi T.
    Bero, Lisa
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (04):
  • [4] [Anonymous], GUID IND DIAB MELL D
  • [5] GENERALIZING THE RESULTS OF RANDOMIZED CLINICAL-TRIALS
    BAILEY, KR
    [J]. CONTROLLED CLINICAL TRIALS, 1994, 15 (01): : 15 - 23
  • [6] Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial
    Barnett, Anthony H.
    Burger, Jude
    Johns, Don
    Brodows, Robert
    Kendall, David M.
    Roberts, Anthony
    Trautmann, Michael E.
    [J]. CLINICAL THERAPEUTICS, 2007, 29 (11) : 2333 - 2348
  • [7] Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea
    Bergenstal, Richard
    Lewin, Andrew
    Bailey, Timothy
    Chang, Denise
    Gylvin, Titus
    Roberts, Victor
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (01) : 65 - 75
  • [8] Retrospective cohort study evaluating exenatide twice daily and long-acting insulin analogs in a Veterans Health Administration population with type 2 diabetes
    Bounthavong, M.
    Tran, J. N.
    Golshan, S.
    Piland, N. F.
    Morello, C. M.
    Blickensderfer, A.
    Best, J. H.
    [J]. DIABETES & METABOLISM, 2014, 40 (04) : 284 - 291
  • [9] Observational research - opportunities and limitations
    Boyko, Edward J.
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2013, 27 (06) : 642 - 648
  • [10] Britton A, 1999, J Health Serv Res Policy, V4, P112